Datar Cancer Genetics Profile
Key Indicators
- Authorised Capital ₹ 125.80 Cr
as on 29-12-2024
- Paid Up Capital ₹ 120.41 Cr
as on 29-12-2024
- Company Age 32 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.38 Cr
as on 29-12-2024
- Revenue 213.84%
(FY 2021)
- Profit 57.08%
(FY 2021)
- Ebitda 96.30%
(FY 2021)
- Net Worth -19.84%
(FY 2021)
- Total Assets 23.97%
(FY 2021)
About Datar Cancer Genetics
The Corporate was formerly known as Datar Genetics Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 125.80 Cr and a paid-up capital of Rs 120.41 Cr.
The company has closed loans amounting to ₹1.38 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Datar Cancer Genetics Private Limited India is Aditi Bhavsar as COMPANY SECRETARY. Sneha Datar, Rajan Datar, and Swati Deshpande serve as directors at the Company.
- CIN/LLPIN
U01110MH1992PTC067409
- Company No.
067409
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jun 1992
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Datar Cancer Genetics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Aditi Bhavsar | Company Secretary | 12-Oct-2022 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sneha Datar  | Director | 01-Apr-2013 | Current |
| Rajan Datar | Director | 25-Mar-2022 | Current |
| Swati Deshpande | Director | 23-Oct-2020 | Current |
Financial Performance of Datar Cancer Genetics.
Datar Cancer Genetics Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 213.84% increase. The company also saw a substantial improvement in profitability, with a 57.08% increase in profit. The company's net worth observed a substantial decline by a decrease of 19.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Datar Cancer Genetics?
In 2021, Datar Cancer Genetics had a promoter holding of 59.03% and a public holding of 40.97%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Blue Leopard Genomic Essentials Private LimitedActive 7 years 5 months
Sneha Datar and Swati Deshpande are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 16 Jan 2023 | ₹9.29 M | Satisfied |
Hdfc Bank Limited Creation Date: 20 Dec 2022 | ₹4.53 M | Satisfied |
How Many Employees Work at Datar Cancer Genetics?
Unlock and access historical data on people associated with Datar Cancer Genetics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Datar Cancer Genetics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Datar Cancer Genetics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
